Today: 11 June 2026
Browse Category

NYSE:JNJ 27 January 2026 - 6 February 2026

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

Procter & Gamble shares rose 1.1% to $158.61 in after-hours trading, outperforming broader market declines. CEO Ma. Fatima D. Francisco sold 8,000 shares at $158 each on Feb. 4, according to a regulatory filing. U.S. jobless claims increased to 231,000, while job openings fell to 6.542 million. P&G’s Gillette Venus announced a partnership with U.S. Figure Skating ahead of the Milano Cortina Winter Games.
6 February 2026
···
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
5 February 2026
··
Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

The FDA issued an early alert on Abiomed Impella RP heart pumps, citing a pressure sensor defect linked to 22 serious injuries but no deaths. Johnson & Johnson shares rose 0.6% to $234.47, holding steady after hours. Traders await further FDA updates and MedTech data at the AF Symposium on Feb. 6. The S&P 500 fell 0.51% while the Dow gained 0.53%.
5 February 2026
··
Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson shares rose 1% to $235.50 Wednesday, bucking a broader market decline. RBC raised its price target to $255, citing strong financials despite ongoing talc litigation. New data showed ERLEADA cut prostate cancer death risk by 51% versus darolutamide. Investors await updates at the AF Symposium on Feb. 6 and a TD Cowen event on March 3.
4 February 2026
···
Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson shares rose about 1% Tuesday to $233.10 after RBC Capital Markets raised its price target, citing ongoing talc litigation risk. The company highlighted new real-world data showing ERLEADA cut death risk by 51% in certain prostate cancer patients. Investors await management’s next comments at the TD Cowen conference on March 3.
4 February 2026
··
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
···
Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson stock price drifts after record-area run as Morgan Stanley upgrade keeps spotlight on new drugs

Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday after peaking near record highs, following a Morgan Stanley upgrade and a price target hike to $262. The FDA approved a new Darzalex Faspro combination for multiple myeloma on Jan. 27. CEO Joaquin Duato’s spouse sold 100,000 shares last week, SEC filings show. J&J forecasts 2026 sales up to $100.5 billion and EPS up to $11.63.
29 January 2026
··
Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson stock price rises as Morgan Stanley upgrades JNJ and FDA clears new Darzalex regimen

Johnson & Johnson shares rose 1.5% to $227.72 Wednesday after Morgan Stanley upgraded the stock and raised its price target to $262. The FDA approved expanded use of J&J’s Darzalex Faspro for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. A regulatory filing showed CEO Joaquin Duato’s spouse sold about $22 million in shares.
29 January 2026
··
Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson stock rises on Darzalex Faspro FDA nod as traders size up drug-pricing risks

Johnson & Johnson shares rose 1.2% to $227.06 after the FDA approved Darzalex Faspro for use with the VRd regimen in newly diagnosed multiple myeloma patients ineligible for stem cell transplant. The approval is based on the CEPHEUS trial, which showed improved outcomes. The move comes as Medicare named 15 drugs for future price negotiations, pressuring the sector.
28 January 2026
··
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
1 2 3 4 … 9

Stock Market Today

  • Hugo Boss Shares Surge 7% as Frasers Group Launches €2 Billion Takeover Offer
    June 11, 2026, 3:49 AM EDT. Hugo Boss shares jumped 6% after Frasers Group, its largest shareholder with a 26% stake, announced a €2 billion ($2.28 billion) cash takeover offer at €38 per share. The bid, representing a 4% premium to Wednesday's close, is not coordinated with Hugo Boss, which said it will thoroughly review the proposal. Frasers supports Hugo Boss's growth strategy and management. Analysts at Citi expect limited near-term price gains but speculate on a potential higher bid. The transaction awaits regulatory approvals and could conclude in H2 2026.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Go toTop